论文部分内容阅读
77例PTa-PTL期膀胱癌,TUR术后一周内开始治疗,E组(39例)用环氧甘醚0.565g加生理盐水50毫升膀胱内灌注,每周一次,连续6周,以后每月1交,共1年。K组(38例)用KLH(Keyhole-Limpe haemocyanin)1毫克皮下注射,另取30毫克加生理盐水30毫升作膀胱灌注,灌药次数及疗程同E组。于肿瘤基底及边缘作多处TUR活检,证实切除肿瘤彻底并绘制膀胱病理图。每3个月复查一次膀胱镜,随访期限最低12个月(平均26.19±5.7月)。对两组的肿瘤复发率、无瘤时限及肿瘤进展率进行比较。 77例患者平均年龄66.6岁。男性74%,PTa期44%;PTL期56%。病理Ⅰ、Ⅱ、Ⅲ级分别为
77 cases of PTA-PTL stage bladder cancer were treated within one week after TUR, and group E (39 cases) was intravesically instilled with epoxy glyme 0.565g plus normal saline 50ml once a week for 6 weeks, and then monthly 1 pay, a total of 1 year. K group (38 cases) was subcutaneously injected with KLH (Keyhole-Limpe haemocyanin) 1 mg, another 30 mg plus normal saline 30 ml was used for bladder instillation. The number and course of medication were the same as those in group E. Multiple TUR biopsies were performed at the base and periphery of the tumor to confirm that the tumor was completely removed and the pathological map of the bladder was drawn. The cystoscope was reviewed every 3 months for a minimum of 12 months (average 26.19±5.7 months). The tumor recurrence rate, no tumor time limit, and tumor progression rate were compared in the two groups. The average age of 77 patients was 66.6 years old. 74% of men, 44% of PTa, and 56% of PTL. Pathological grades I, II, and III are